Fig 1 shows the measles disease progression model that was used

Fig. 1 shows the measles disease progression model that was used to calculate Regorafenib the DALYs. Each box represents a different health outcome defined by a specific duration (in years) and disability weight (0 = best possible health state, 1 = worst possible health state) (data not shown). The acute symptomatic illness is highlighted in yellow since it is where the incident measles cases were entered into the model for the DALYs calculation. The possible endpoints considered were

recovery (R), death (fatal cases) and long term disabilities. The Greek letters describe the transition probabilities for moving from one health outcome to the next. The DALYs attributable to each health outcome, including those attributable to fatal cases, were derived through this disease model and eventually added in order to obtain the overall burden of measles. Fig. 2 plots vaccination coverage against estimated burden, separately for each year of the study period, and shows the negative linear relationship between measles vaccination coverage and the log burden of DALYs/100,000

by calendar year. Data points were more often located above 90% vaccination coverage during the entire study period than below. For more recent years (2009–2011) some observations showed high DALYs/100,000 estimates, despite reported national vaccination coverage above 90%. Using Vemurafenib price data from a 6-year period from 29 EU/EEA MS, we observed a significant negative association between measles vaccination coverage and the estimated burden of measles in a given year. This result is in the expected direction,

and importantly takes between-country heterogeneity too in burden and time-varying effects (i.e., outbreak years) into account. Our finding is also consistent with the negative association recently reported between vaccination coverage and measles incidence at the global level in the period 1980–2008 [28]. By investigating the relationship between vaccination coverage and DALYs – as opposed to incidence – we are in fact estimating the relationship between the success of national vaccination programmes and the estimated health burden (i.e., from both mortality and morbidity) attributable to infection, hence also accounting for possible variations in the age-distribution of cases between countries (to which the DALY measure obtained from our disease model is sensitive). For instance, two countries with similar incidence rates might have a very different age distribution of cases, and therefore will differ in estimated DALYs. In 2011, an incidence rate of 0.06 cases/100,000 was observed for a certain country (of which 25.7% cases were below the age of 10 years); for the same year, another country (74.1% cases below the age of 10 years) had a very similar incidence rate, of 0.05 cases/100,000. The estimated burden was 0.19 DALYS/100,000 for the first country, but three-fold greater, 0.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>